caribou biosciences stock ticker

View daily weekly or monthly format back to when Caribou Biosciences Inc. Discover historical prices for CRBU stock on Yahoo Finance.

Intellia Therapeutics Inc Stock History The Story Of A Crispr Gene Editing Pioneer The Motley Fool

Caribou is a leader in the CRISPR field successfully leveraging its proprietary genome-editing technology to develop allogeneic cell therapies that are potentially transformative for patients.

. Shares Outstanding Ticker 6084M Dividends Ownership Peers Risk Short Interest 860 Shares Short 397M Days to Cover 521 24M Beta 172 Altman Z Score 712. CRBU stock quote history news and other vital information to help you with your stock trading and investing. Market Cap 59258M Shares Out 6084M 10 Day Average Volume 065M Dividend - Dividend Yield - Beta - YTD Change -3545 RATIOSPROFITABILITY EPS TTM -141 PE.

It involved in developing a pipeline of genome-edited off-the. CRBU stock news and headlines to help you in your trading and investing decisions. Stock analysis for Caribou Biosciences Inc CRBUNASDAQ GS including stock price stock chart company news key statistics fundamentals and company profile.

Caribou Biosciences Inc. 1 day agoItem 701 Regulation FD Disclosure. Get the latest Caribou Biosciences Inc CRBU real-time quote historical performance charts and other financial information to help you make more informed trading and investment decisions.

Caribou Biosciences Inc. Is a clinical-stage CRISPR genome-editing biopharmaceutical company. CRBU Stock Price News Info The Motley Fool Premium Services Stock Advisor Return 355 112 Rule Breakers High-growth Stocks Return.

SP Futures 376850 -025-001 Dow Futures 3218500 700002 Nasdaq Futures 1094800 350003 Russell 2000 Futures 179300 -030-002 Crude Oil 8934 -066. On November 3 2022 Caribou Biosciences Inc. Find the latest Caribou Biosciences Inc.

Caribou Biosciences Inc. Stock Quote. The Company issued a press release announcing that a trial-in-progress abstract for the.

Get the latest Caribou Biosciences Inc. Is a clinical-stage genome-editing. Quotes 5-day view Delayed Nasdaq More quotes Estimated financial data e USD More Financials Company Caribou Biosciences Inc.

Caribou Biosciences Inc a clinical-stage biopharmaceutical company engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic. CRBU shares are trading lower after the company reported additional data from its CB-010 allogeneic CAR-T cell therapy Phase 1. Find real-time CRBU - Caribou Biosciences Inc stock quotes company profile news and forecasts from CNN Business.

Caribou Biosciences Is Going Public Here S An Intro To The Company And Their Revolutionary Gene Editing Technology R Investing